DataMeds AI, Inc.

MEDS

Nasdaq; shops; SIC 5122, Wholesale-Drugs, Proprietaries & Druggists' Sundries; CIK 0002030763

None

No letter

5 of 13 inputs computable; 7 are required, with a score in every sleeve

Scoreboard	
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $30.5M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	dilution, short runway, late filer, thin... not computable: distress
Inputs computable	5 of 13
Graded from	filings received through Apr 24, 2026 208 days before the rescan; latest periodic filing 10-Q received Nov 13, 2026
Last close	$0.61 2026-11-17; market equity $3.5M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 20, 2026

in 2022, we are a holding company for existing and future planned operating companies centered around pharmaceuticals and healthcare services. We seek to be a micro health ecosystem, with a portfolio of companies consisting of a pharmacy, wholesale operations, and a technology division that provides a novel platform for hub and clinical services. We are focused on improving the lives of patients while delivering unique solutions for pharmacies, providers, pharmaceutical manufacturers, and payors.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 50.4						
Gross profitability	(21.1%)	43.7%		100.0	224	2025-12-31
Return on invested capital	not computable	11.5%				
one or more required annual facts are missing						
Accruals ratio	(206.0%)	(4.9%)		0.7	269	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	not computable	1.2 pts			
five annual gross margins are required; found 2					
Solvency, sleeve percentile 98.1					
Altman Z double-prime	(38.68)	1.92	97.0	198	2025-12-31
Net debt to EBITDA	not computable	1.46x			
EBITDA must exceed $100,000					
Interest coverage	not computable	2.70x			
one or more required annual facts are missing					
Current ratio	0.09x	1.34x	99.3	275	2025-12-31
Growth and financing, sleeve percentile 95.2					
Revenue growth, three-year compound	not computable	1.8%			
four annual observations are required; found 2					
Free cash flow growth, three-year compound	not computable	4.7%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	13.3%			
one or more required annual facts are missing					
Asset growth, three years	not computable	3.1%			
four annual observations are required; found 2					
Net share issuance, one year	101.9%	(0.6%)	95.2	208	2026-03-06

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 101.9%
Short runway	cash runway is 0.4 months
Late filer	found 4 NT 10-K/Q filings in the last eight quarters
Thin data	5 of 13 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-17 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(90.9%)	(0.8%)	2
Distance from 52-week high	(98.0%)	(23.1%)	2
EBIT to enterprise value	(439.0%)	5.1%	1
Free cash flow yield	not computable	3.9%	
Book value to price	(0.46)	0.36	6
Sales to price	6.37	1.61	84
Composite equity issuance, five years	not computable	(17.1%)	
Relative strength against the sector, log excess return	(2.31)	0.08	2
Twelve-month failure probability, CHS model	not computable	0.04%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$476,598
Operating cash flow, four quarters	-$15.5M
Months of runway	0.4
Days since last periodic filing	5 (10-Q received Nov 13, 2026)
Median daily dollar volume, 63 sessions	$839,557

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	-$6.4M	2025-12-31	2026-03-20	10-K	26-012004
2	assets	us-gaap:Assets	$30.5M	2025-12-31	2026-03-20	10-K	26-012004
3	net income	us-gaap:NetIncomeLoss	-$101.3M	2025-12-31	2026-03-20	10-K	26-012004
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$10.9M	2025-12-31	2026-03-20	10-K	26-012004
5	assets	us-gaap:Assets	$57.3M	2024-12-31	2026-03-20	10-K	26-012004
6	current assets	us-gaap:AssetsCurrent	$2.8M	2025-12-31	2026-03-20	10-K	26-012004
7	current liabilities	us-gaap:LiabilitiesCurrent	$29.8M	2025-12-31	2026-03-20	10-K	26-012004
8	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$111.0M	2025-12-31	2026-03-20	10-K	26-012004
9	operating income	us-gaap:OperatingIncomeLoss	-$93.7M	2025-12-31	2026-03-20	10-K	26-012004
10	book equity	us-gaap:StockholdersEquity	-$12.4M	2025-12-31	2026-03-20	10-K	26-012004
11	liabilities	us-gaap:Liabilities	$42.9M	2025-12-31	2026-03-20	10-K	26-012004
12	total debt	us-gaap:LongTermDebt	$23.5M	2025-12-31	2026-03-20	10-K	26-012004
13	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$42,571	2025-12-31	2026-03-20	10-K	26-012004
14	depreciation amortization	us-gaap:Depreciation	$158,804	2025-12-31	2026-03-20	10-K	26-012004
15	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$23.3M	2025-12-31	2026-03-20	10-K	26-012004
16	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$18.1M	2024-12-31	2026-03-20	10-K	26-012004
17	shares outstanding	dei:EntityCommonStockSharesOutstanding	104,871,987	2026-03-06	2026-04-24	10-K/A	26-018958
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	51,944,397	2025-03-20	2025-03-25	10-K	25-000612

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.